Protalix BioTherapeutics, Inc. (PLX)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Dror Bashan
|
President, CEO & Director | 807.9k | -- | 1967 |
|
Mr. Gilad Mamlok
|
Senior VP, CFO Treasurer & Secretary | 309.42k | -- | 1968 |
|
Mr. Yaron Naos B.Sc., MBA
|
SVP & COO | 418.14k | -- | 1964 |
|
Ms. Yael Fellous
|
Vice President of Human Resources | -- | -- | -- |
Protalix BioTherapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 226
Description
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack, New Jersey.
Corporate Governance
Upcoming Events
November 12, 2026 at 1:30 PM UTC
Protalix BioTherapeutics, Inc. Earnings Date
